ClinicalTrials.gg
CompletedNCT07583628Updated May 13, 2026

CMC-1 Replacement Arthroplasty Versus Trapeziectomy

An observational study in Osteoarthritis in the Carpometacarpal (CMC) Joint, sponsored by Karolinska Institutet. Completed. Open to participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Sponsored by Karolinska Institutet · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,000
Ages
45 Years and older
Sex
All
01

Study summary

Thumb carpometacarpal (CMC-1) osteoarthritis is a common condition causing pain and disability, particularly among middle-aged and older women. When non-operative treatment fails, surgery is indicated. In Sweden, trapeziectomy (TE), with or without tendon-based adjuncts, is the standard procedure and recommended in the National Care Program introduced in 2022. However, total joint arthroplasty (TJA) has gained popularity because of reports of faster recovery and improved early function, although concerns remain regarding complications, durability, and cost. Comparative studies are therefore needed.

The aim of this study is to compare patient-reported outcomes after dual-mobility TJA versus TE, with or without tendon-based adjuncts, for CMC-1 osteoarthritis using data from the Swedish Hand Surgery Quality Register (HAKIR). To reduce bias in observational data, the study will emulate a hypothetical randomized target trial.

This registry-based cohort study will include adults aged 45 years or older undergoing primary surgery for CMC-1 osteoarthritis. Patients with previous CMC-1 surgery, bilateral procedures, inflammatory joint disease, or extensive missing baseline data will be excluded. Baseline is defined as the date of surgery, and patients will be followed using patient-reported outcome measures collected preoperatively and at 3 and 12 months.

The primary outcome is change in pain on load measured with the HQ-8 questionnaire at 12 months. Secondary outcomes include pain at 3 months, low pain levels at 12 months, other HQ-8 domains, QuickDASH score, patient satisfaction, grip and pinch strength, thumb range of motion, time to reoperation, and postoperative complications.

Potential confounders will be identified using a directed acyclic graph (DAG). Measured confounders include age, sex, surgical centre, calendar year, baseline pain, baseline function, and smoking. Unmeasured factors such as surgeon preference, patient preference, and disease severity not captured in the registry may still cause residual confounding.

Primary analyses will use linear mixed-effects regression to compare adjusted mean pain outcomes between groups at 12 months while accounting for clustering by patient and centre. Secondary outcomes will be analysed using ordinal logistic regression, Cox proportional hazards regression, and logistic regression. Missing data will be handled using multiple imputation, and sensitivity analyses using inverse probability weighting will assess the impact of reoperations and selection bias

02

Conditions studied

  • Osteoarthritis in the Carpometacarpal (CMC) Joint

Browse trials for

Keywords

  • thumb base
  • osteoarthritis
  • PROM
  • trapeziectomy
  • joint replacement
  • CMC-1
03

In context

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

This study's planned enrollment of 1,000 is above the median of 100 across 602 observational studies indexed under Osteoarthritis.

Browse Osteoarthritis studies →

Lead sponsor

Karolinska Institutet is the lead sponsor of 1,150 studies on the registry; 276 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Eligible patients are adults aged ≥45 years with a diagnosis of CMC-1 osteoarthritis (ICD-10 code M18) who have failed non-operative treatment and are scheduled for primary CMC-1 surgery.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

adults aged ≥45 years with a diagnosis of CMC-1 osteoarthritis (ICD-10 code M18) who have failed non-operative treatment and are scheduled for primary CMC-1 surgery.

Exclusion criteria

Exclusion Criteria:

  • Bilateral CMC-1 surgery or other simultaneous hand interventions
  • Previous CMC-1 surgery on the affected hand
  • Inflammatory joint disease affecting the hands (e.g., rheumatoid arthritis, systemic lupus erythematosus)
  • 30% missing baseline (preoperative) variables
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Target follow-up
12 Months
Patient registry
Yes

Groups and cohorts

  • Adults diagnosed with and operated for CMC1 OA (ICD-10 M18*)

    1. Trapeziectomy (TE) with or without tendon adjunct according to routine practice with Flexor Carpi Radialis/Extensor Carpi Radialis Longus/Abductor Pollicis Longus/Palmaris Longus). 2. Total joint thumb base dual mobility arthroplastyDual mobility TJA

06

What researchers measure

Primary outcomes

  1. Change from baseline to 12 months in pain on load motion measured with the HAKIR questionnaire.

    Pain on load motion assessed using the HQ-8 patient-reported outcome questionnaire. Responses are reported on an 11-point numerical rating scale ranging from 0 (no symptoms or discomfort) to 100 (worst imaginable symptoms or discomfort) in increments of 10.

    Time frame: Baseline and 12 months postoperatively

Secondary outcomes

  1. Change from baseline to 12 months in pain on unloaded motion measured with the HAKIR questionnaire

    Pain on unloaded motion assessed using the HQ-8 patient-reported outcome questionnaire. Responses are reported on an 11-point numerical rating scale ranging from 0 (no symptoms or discomfort) to 100 (worst imaginable symptoms or discomfort) in increments of 10.

    Time frame: Baseline and 12 months after surgery

  2. Change from baseline to 12 months in pain at rest measured with the HQ-8 questionnaire

    Pain at rest assessed using the HQ-8 patient-reported outcome questionnaire. Responses are reported on an 11-point numerical rating scale ranging from 0 (no symptoms or discomfort) to 100 (worst imaginable symptoms or discomfort) in increments of 10.

    Time frame: Baseline and 12 months postoperatively

  3. Change from baseline to 12 months in stiffness measured with the HQ-8 questionnaire

    Stiffness assessed using the HQ-8 patient-reported outcome questionnaire. Responses are reported on an 11-point numerical rating scale ranging from 0 (no symptoms or discomfort) to 100 (worst imaginable symptoms or discomfort) in increments of 10.

    Time frame: Baseline and 12 months postoperatively

  4. Change from baseline to 12 months in weakness measured with the HQ-8 questionnaire

    Weakness assessed using the HQ-8 patient-reported outcome questionnaire. Responses are reported on an 11-point numerical rating scale ranging from 0 (no symptoms or discomfort) to 100 (worst imaginable symptoms or discomfort) in increments of 10.

    Time frame: Baseline and 12 months postoperatively

  5. Change from baseline to 12 months in activities of daily living measured with the HQ-8 questionnaire

    Activities of daily living assessed using the HQ-8 patient-reported outcome questionnaire. Responses are reported on an 11-point numerical rating scale ranging from 0 (no symptoms or discomfort) to 100 (worst imaginable symptoms or discomfort) in increments of 10.

    Time frame: Baseline and 12 months postoperatively

  6. Change from baseline to 12 months in Quick Disabilities of Arm, Shoulder and Hand Questionnaire (Quick DASH)

    Upper extremity disability and symptoms assessed using the Quick Disabilities of the Arm, Shoulder and Hand (QuickDASH) questionnaire. Scores range from 0 to 100, where higher scores indicate greater disability and worse upper extremity function.

    Time frame: Baseline and 12 months postoperatively

  7. Change in key pinch strength

    kg

    Time frame: Baseline and 12 months postoperatively

  8. Change in grip strength

    jamar (kg)

    Time frame: Baseline and 12 months postoperatively

  9. Change in thumb radial abduction

    radial abduction (degrees)

    Time frame: Baseline and 12 months postoperatively

  10. Change in thumb plamar abduction

    palmar abduction (degrees)

    Time frame: From preoperatively to 12 months postoperatively

  11. Time to first reoperation* of the index hand

    Time frame: primary horizon: 12 months; secondary: maximum available follow-up

  12. Risk of any (non-reoperation) complication within 12 months

    occurrence of any registered postoperative complication of the index hand recorded in HAKIR

    Time frame: within 12 months after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Undecided — Data generated and analyzed during this study are stored within HAKIR and are subject to Swedish data protection legislation and the GDPR. Due to legal and ethical restrictions, individual-level participant data cannot be made publicly available. Access to de-identified study data may be granted to qualified researchers upon reasonable request and subject to approval by the Swedish Ethical Review Authority and the HAKIR steering committee. Access to the statistical code will be granted after reasonable request.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2011 to primary completion in Dec 2025, 179 months.

Of 146 non-industry observational studies under Osteoarthritis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 97. This study's 179 months is above that.

Counting every sponsor, half of 228 studies reached it within 57 months; a quarter within 21 and three quarters within 141.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 13, 2026
StartActual
Jan 1, 2011
Primary completionActual
Dec 31, 2025
CompletionActual
Dec 31, 2025
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07583628
Responsible party
Maria Wilcke (Associate Professor, Karolinska Institutet) — Principal investigator
First posted
May 13, 2026
Start date
Jan 1, 2011
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
May 13, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion